Study design and participants
NAFLD, fatty liver disease
DRUG-INDUCED LIVER DISEASE, VIRUS, AUTOIMMUNE LIVER DISEASE, METABOLIC DISEASE, HEPATITIS B, DISEASES
This study was designed as a randomized, controlled trial. Participants were recruited from Shuguang Hospital Affiliated to the Shanghai University of Traditional Chinese Medicine from September 2020 to September 2021 who meet the diagnostic of NAFLD. The diagnostic criteria are as follows: (1) No history of alcohol consumption or consumption of less than 30 g of alcohol per day in men (less than 20 g per day in women). (2) Except for certain diseases that can lead to NAFLD including Hepatitis B and C virus, autoimmune liver disease, drug-induced liver disease, genetic metabolic disease, etc. (3) Imaging features of the liver conform with the diagnostic criteria for diffuse fatty liver disease (Eligible patients were between 18 and 70 years old, consistent with the diagnosis of NAFLD; ALT, AST and GGT<5×upper limit of normal (ULN); BMI ≤ 30kg/m